NO20042673L - Acetylenderivaer som har mGluR5 antagonistisk aktivitet - Google Patents

Acetylenderivaer som har mGluR5 antagonistisk aktivitet

Info

Publication number: NO20042673L
Authority: NO; Norway
Prior art keywords: antagonistic activity; acetylene derivatives; mglur5; mglur5 antagonistic; acetylene
Prior art date: 2001-12-04

Application number

NO20042673A

Other languages

English (en)

Other versions

NO327005B1 (no

Inventor

Fabrizio Gasparini

Yves Auberson

Ofner Silvio

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-04

Filing date

2004-06-25

Publication date

2004-06-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9926969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20042673(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-06-25 Application filed by Novartis Ag filed Critical Novartis Ag

2004-06-25 Publication of NO20042673L publication Critical patent/NO20042673L/no

2009-04-06 Publication of NO327005B1 publication Critical patent/NO327005B1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/23—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Indole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Quinoline Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)

NO20042673A 2001-12-04 2004-06-25 Acetylenderivaer som har mGluR5 antagonistisk aktivitet NO327005B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0128996.6A GB0128996D0 (en)	2001-12-04	2001-12-04	Organic compounds
PCT/EP2002/013670 WO2003047581A1 (en)	2001-12-04	2002-12-03	Acetylene derivatives having mglur 5 antagonistic activity

Publications (2)

Publication Number	Publication Date
NO20042673L true NO20042673L (no)	2004-06-25
NO327005B1 NO327005B1 (no)	2009-04-06

Family

ID=9926969

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20042673A NO327005B1 (no)	2001-12-04	2004-06-25	Acetylenderivaer som har mGluR5 antagonistisk aktivitet

Country Status (31)

Country	Link
US (4)	US7348353B2 (no)
EP (1)	EP1453512B8 (no)
JP (2)	JP4176020B2 (no)
KR (2)	KR100980901B1 (no)
CN (2)	CN100430059C (no)
AR (2)	AR037682A1 (no)
AT (1)	ATE327755T1 (no)
AU (1)	AU2002358585B2 (no)
BR (1)	BR0214666A (no)
CA (1)	CA2466560C (no)
CO (1)	CO5590929A2 (no)
CY (1)	CY1105460T1 (no)
DE (1)	DE60211944T2 (no)
DK (1)	DK1453512T3 (no)
EC (1)	ECSP045139A (no)
EG (1)	EG24936A (no)
ES (1)	ES2263842T3 (no)
GB (1)	GB0128996D0 (no)
HU (1)	HU229429B1 (no)
IL (1)	IL161990A0 (no)
MX (1)	MXPA04005456A (no)
MY (1)	MY137774A (no)
NO (1)	NO327005B1 (no)
NZ (1)	NZ533266A (no)
PE (1)	PE20030640A1 (no)
PL (1)	PL212996B1 (no)
PT (1)	PT1453512E (no)
RU (1)	RU2341515C2 (no)
TW (1)	TWI328578B (no)
WO (1)	WO2003047581A1 (no)
ZA (1)	ZA200403713B (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0128996D0 (en) *	2001-12-04	2002-01-23	Novartis Ag	Organic compounds
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
GB0325956D0 (en) *	2003-11-06	2003-12-10	Addex Pharmaceuticals Sa	Novel compounds
EP1734963A4 (en)	2004-04-02	2008-06-18	Merck & Co Inc	METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
GB0503646D0 (en) *	2005-02-22	2005-03-30	Novartis Ag	Organic compounds
GB0508314D0 (en) *	2005-04-25	2005-06-01	Novartis Ag	Organic compounds
GB0508319D0 (en) *	2005-04-25	2005-06-01	Novartis Ag	Organic compounds
GB0508318D0 (en) *	2005-04-25	2005-06-01	Novartis Ag	Organic compounds
GB0514296D0 (en) *	2005-07-12	2005-08-17	Novartis Ag	Organic compounds
EP2069305A2 (en) *	2006-09-11	2009-06-17	Novartis AG	Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2559319T3 (es)	2007-06-04	2016-02-11	Synergy Pharmaceuticals Inc.	Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2012254934B2 (en) *	2007-10-12	2013-10-17	Novartis Ag	Metabotropic glutamate receptor modulators for the treatment of Parkinson's disease
US20100249136A1 (en) *	2007-10-12	2010-09-30	Daniel Umbricht	Organic compounds
CA2726917C (en)	2008-06-04	2018-06-26	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
BRPI0913642A2 (pt) *	2008-06-30	2015-11-24	Novartis Ag	produtos de combinação
CA2732095C (en) *	2008-08-12	2017-04-25	Novartis Ag	Processes for the preparation of 4-oxo-octahydro-indole-1-carbocylic acid methyl ester and derivatives thereof
US8334287B2 (en)	2009-07-17	2012-12-18	Hoffmann-La Roche Inc.	Imidazoles
EP2456438A2 (en)	2009-07-23	2012-05-30	Novartis AG	Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
JO3250B1 (ar)	2009-09-22	2018-09-16	Novartis Ag	إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
EP2490691A1 (en)	2009-10-20	2012-08-29	Novartis AG	Use of 1h-quinazoline-2,4-diones
CA2797854A1 (en)	2010-04-30	2011-11-03	Novartis Ag	Predictive markers useful in the treatment of fragile x syndrome (fxs)
US20130096145A1 (en)	2010-06-24	2013-04-18	Novartis Ag	Use of 1H-quinazoline-2,4-diones
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
US20130274294A1 (en) *	2010-12-20	2013-10-17	David Carcache	4-(Hetero)Aryl-Ethynyl-Octahydro-Indole-1-Esters
WO2012101058A1 (en)	2011-01-24	2012-08-02	Novartis Ag	4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
AU2012210652B2 (en)	2011-01-27	2016-04-07	Novartis Ag	Use of nicotinic acetylcholine receptor alpha 7 activators
CA2830458A1 (en)	2011-03-18	2012-09-27	Novartis Ag	Combinations of alpha 7 nicotinic acetylcholine receptor activators and mglur5 antagonists for use in dopamine induced dyskinesia in parkinson's disease
CA2846503A1 (en)	2011-09-07	2013-03-14	Novartis Ag	Use of 1h-quinazoline-2,4-diones for use in the prevention or treatment of photosensitive epilepsy
WO2013131981A1 (en)	2012-03-08	2013-09-12	Novartis Ag	Predictive markers useful in the diagnosis and treatment of fragile x syndrome (fxs)
GB201215033D0 (en)	2012-08-23	2012-10-10	Novartis Ag	Diazepinone derivatives
JP2016508159A (ja)	2013-01-15	2016-03-17	ノバルティスアーゲー	アルファ７ニコチン性アセチルコリン受容体アゴニストの使用
MX362819B (es)	2013-01-15	2019-02-18	Novartis Ag	Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia.
CA2905438A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
EP2968439A2 (en)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
EA201592263A1 (ru)	2013-06-05	2016-05-31	Синерджи Фармасьютикалз, Инк.	Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
SG11201509178TA (en) *	2013-06-12	2015-12-30	Novartis Ag	Modified release formulation
GB201312800D0 (en)	2013-07-17	2013-08-28	Heptares Therapeutics Ltd	mGlu5 modulators
CN105669686B (zh) *	2014-11-19	2018-08-03	上海合全药业股份有限公司	一种6-(叔丁氧羰基)八氢呋喃[2,3-c]吡啶-4-羧酸的合成方法
EP3661501A1 (en)	2017-07-31	2020-06-10	Novartis AG	Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use
KR20250048143A (ko)	2017-07-31	2025-04-07	노파르티스 아게	코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
MX2021008827A (es) *	2019-01-29	2021-09-08	Novartis Ag	Uso de un antagonista de mglur5 para el tratamiento de la tolerancia a los analgesicos opioides.
KR20220097405A (ko) *	2019-11-05	2022-07-07	클라에스 툴린	포유동물에서의 혹사의 예방 및/또는 치료에 사용하기 위한 4-[5-[(rac)-1-[5-(3-클로로페닐)-3-이속사졸일]에톡시]-4-메틸-4H-1,2,4-트리아졸-3-일]피리딘
KR102850517B1 (ko)	2020-07-17	2025-08-25	노파르티스 아게	오피오이드 사용 감소 치료에 사용하기 위한 mglur5 길항제 마보글루란트
US20240050408A1 (en)	2020-12-11	2024-02-15	Novartis Ag	Use of mglur5 antagonists for treating amphetamine addiction
US20240082215A1 (en)	2020-12-14	2024-03-14	Novartis Ag	Use of mglur5 antagonists for treating gambling disorder

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2741009A1 (de) *	1976-09-22	1978-03-23	Sandoz Ag	4-styryl-4-indolinol-derivate, ihre verwendung und herstellung
DE2802833A1 (de)	1978-01-23	1979-07-26	Sandoz Ag	4-styryl-4-indolinol-derivate, ihre verwendung und herstellung
US5264456A (en) *	1989-12-29	1993-11-23	Allergan, Inc.	Acetylenes disubstituted with a furyl group and a substituted phenyl group having retinoid like activity
US5284957A (en) *	1992-09-03	1994-02-08	Eli Lilly And Company	Excitatory amino acid receptor antagonists
US5593994A (en)	1994-09-29	1997-01-14	The Dupont Merck Pharmaceutical Company	Prostaglandin synthase inhibitors
EP0849256B1 (en)	1995-08-22	2005-06-08	Japan Tobacco Inc.	Amide compounds and use of the same
EP2223920A3 (en)	1996-06-19	2011-09-28	Aventis Pharma Limited	Substituted azabicyclic compounds
TW544448B (en) *	1997-07-11	2003-08-01	Novartis Ag	Pyridine derivatives
EP1085010B1 (en)	1998-06-04	2004-03-10	Kumiai Chemical Industry Co., Ltd.	Phenylacetylene derivatives and agricultural/horticultural bactericides
BR9914215A (pt)	1998-10-02	2001-07-03	Novartis Ag	Antagonistas de mglur5 para o tratamento da dor e da ansiedade
DZ3209A1 (fr)	1999-07-06	2001-01-11	Lilly Co Eli	Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine.
GB0007108D0 (en)	2000-03-23	2000-05-17	Novartis Ag	Organic compounds
CA2426430C (en)	2000-10-20	2014-10-07	Biocryst Pharmaceuticals, Inc.	Biaryl compounds as serine protease inhibitors
SK8402003A3 (en)	2000-12-04	2004-04-06	Hoffmann La Roche	Phenylethenyl or phenylethinyl derivatives as glutamate receptor or antagonists
GB0103045D0 (en)	2001-02-07	2001-03-21	Novartis Ag	Organic Compounds
US7138404B2 (en)	2001-05-23	2006-11-21	Hoffmann-La Roche Inc.	4-aminopyrimidine derivatives
TW200303309A (en)	2001-12-04	2003-09-01	Bristol Myers Squibb Co	Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors
RU2004120784A (ru)	2001-12-04	2005-08-10	Ф.Хоффманн-Ля Рош Аг (Ch)	Замещенные 2-аминоциклоалканкарбоксамиды и их применение в качестве ингибиторов цистеиновой протеазы
GB0128996D0 (en) *	2001-12-04	2002-01-23	Novartis Ag	Organic compounds

2001
- 2001-12-04 GB GBGB0128996.6A patent/GB0128996D0/en not_active Ceased
2002
- 2002-12-01 EG EG2002121297A patent/EG24936A/xx active
- 2002-12-02 AR ARP020104641A patent/AR037682A1/es not_active Application Discontinuation
- 2002-12-02 PE PE2002001157A patent/PE20030640A1/es not_active Application Discontinuation
- 2002-12-02 TW TW091134933A patent/TWI328578B/zh not_active IP Right Cessation
- 2002-12-03 KR KR1020107002745A patent/KR100980901B1/ko not_active Expired - Fee Related
- 2002-12-03 RU RU2004120781/04A patent/RU2341515C2/ru not_active IP Right Cessation
- 2002-12-03 DK DK02792867T patent/DK1453512T3/da active
- 2002-12-03 BR BR0214666-5A patent/BR0214666A/pt not_active Application Discontinuation
- 2002-12-03 KR KR1020047008477A patent/KR100959204B1/ko not_active Expired - Fee Related
- 2002-12-03 AU AU2002358585A patent/AU2002358585B2/en not_active Ceased
- 2002-12-03 WO PCT/EP2002/013670 patent/WO2003047581A1/en not_active Ceased
- 2002-12-03 ES ES02792867T patent/ES2263842T3/es not_active Expired - Lifetime
- 2002-12-03 CN CNB028232968A patent/CN100430059C/zh not_active Expired - Lifetime
- 2002-12-03 PL PL368739A patent/PL212996B1/pl unknown
- 2002-12-03 JP JP2003548836A patent/JP4176020B2/ja not_active Expired - Lifetime
- 2002-12-03 MY MYPI20024525A patent/MY137774A/en unknown
- 2002-12-03 HU HU0402191A patent/HU229429B1/hu unknown
- 2002-12-03 DE DE60211944T patent/DE60211944T2/de not_active Expired - Lifetime
- 2002-12-03 PT PT02792867T patent/PT1453512E/pt unknown
- 2002-12-03 EP EP02792867A patent/EP1453512B8/en not_active Expired - Lifetime
- 2002-12-03 US US10/497,363 patent/US7348353B2/en not_active Expired - Lifetime
- 2002-12-03 AT AT02792867T patent/ATE327755T1/de active
- 2002-12-03 NZ NZ533266A patent/NZ533266A/en not_active IP Right Cessation
- 2002-12-03 CN CN200810166366.0A patent/CN101366714B/zh not_active Expired - Lifetime
- 2002-12-03 IL IL16199002A patent/IL161990A0/xx not_active IP Right Cessation
- 2002-12-03 MX MXPA04005456A patent/MXPA04005456A/es active IP Right Grant
- 2002-12-03 CA CA2466560A patent/CA2466560C/en not_active Expired - Fee Related
2004
- 2004-05-14 ZA ZA2004/03713A patent/ZA200403713B/en unknown
- 2004-06-04 EC EC2004005139A patent/ECSP045139A/es unknown
- 2004-06-07 CO CO04053105A patent/CO5590929A2/es active IP Right Grant
- 2004-06-25 NO NO20042673A patent/NO327005B1/no not_active IP Right Cessation
2006
- 2006-08-03 CY CY20061101091T patent/CY1105460T1/el unknown
2008
- 2008-02-29 US US12/040,081 patent/US20080146647A1/en not_active Abandoned
- 2008-07-09 JP JP2008179005A patent/JP5036648B2/ja not_active Expired - Lifetime
2011
- 2011-09-22 US US13/239,467 patent/US8536229B2/en not_active Expired - Lifetime
2012
- 2012-11-20 AR ARP120104356A patent/AR088921A2/es not_active Application Discontinuation
2013
- 2013-08-15 US US13/967,719 patent/US20130331568A1/en not_active Abandoned

Also Published As

Publication number	Publication date
RU2341515C2 (ru)	2008-12-20
WO2003047581A1 (en)	2003-06-12
EP1453512B8 (en)	2006-07-19
AR088921A2 (es)	2014-07-16
CN101366714B (zh)	2014-09-17
NO327005B1 (no)	2009-04-06
KR20050044657A (ko)	2005-05-12
DE60211944T2 (de)	2007-05-16
AR037682A1 (es)	2004-12-01
CY1105460T1 (el)	2010-04-28
AU2002358585A1 (en)	2003-06-17
CO5590929A2 (es)	2005-12-30
HUP0402191A2 (hu)	2005-02-28
IL161990A0 (en)	2005-11-20
KR100980901B1 (ko)	2010-09-07
CN100430059C (zh)	2008-11-05
HUP0402191A3 (en)	2010-03-29
PT1453512E (pt)	2006-10-31
US20050065191A1 (en)	2005-03-24
CA2466560C (en)	2010-07-27
MXPA04005456A (es)	2004-10-11
CA2466560A1 (en)	2003-06-12
EP1453512A1 (en)	2004-09-08
EP1453512B1 (en)	2006-05-31
CN1592623A (zh)	2005-03-09
KR20100020044A (ko)	2010-02-19
NZ533266A (en)	2005-02-25
HK1071510A1 (en)	2005-07-22
TW200304910A (en)	2003-10-16
AU2002358585B2 (en)	2006-01-19
JP5036648B2 (ja)	2012-09-26
CN101366714A (zh)	2009-02-18
PE20030640A1 (es)	2003-09-12
RU2004120781A (ru)	2006-01-10
HU229429B1 (en)	2013-12-30
TWI328578B (en)	2010-08-11
GB0128996D0 (en)	2002-01-23
JP2005514381A (ja)	2005-05-19
PL368739A1 (en)	2005-04-04
ES2263842T3 (es)	2006-12-16
DK1453512T3 (da)	2006-08-28
EG24936A (en)	2011-01-11
JP4176020B2 (ja)	2008-11-05
KR100959204B1 (ko)	2010-05-19
PL212996B1 (pl)	2012-12-31
BR0214666A (pt)	2004-11-03
JP2008303226A (ja)	2008-12-18
DE60211944D1 (de)	2006-07-06
ECSP045139A (es)	2004-07-23
US20080146647A1 (en)	2008-06-19
ATE327755T1 (de)	2006-06-15
US8536229B2 (en)	2013-09-17
US20120010263A1 (en)	2012-01-12
ZA200403713B (en)	2005-10-26
US7348353B2 (en)	2008-03-25
MY137774A (en)	2009-03-31
US20130331568A1 (en)	2013-12-12

Publication	Publication Date	Title
NO20042673L (no)	2004-06-25	Acetylenderivaer som har mGluR5 antagonistisk aktivitet
DK1414803T3 (da)	2013-03-25	Pyrazolylcarboxanilider som fungicider
DK1385825T3 (da)	2007-11-05	Substituerede 2-pyridincyclohexan-1,4-diaminderivater
NO20034439L (no)	2003-12-02	Benzamidinderivater
IL169378A0 (en)	2007-07-04	Benzoazolypiperazine derivatives having vr1 antagonistic activity
ATE361281T1 (de)	2007-05-15	Substituierte phenylderivate
ATE392813T1 (de)	2008-05-15	Fungizide wirkstoffkombination
DE50309032D1 (de)	2008-03-06	Fungizide wirkstoffkombinationen
NO20044654L (no)	2004-10-28	Piperidinoylpiperidiner som 5-HTIF-agonister
DE60309013D1 (de)	2006-11-23	Knoten
ATE319451T1 (de)	2006-03-15	Tetrahydrochinolin-derivate
DK1638928T3 (da)	2011-01-17	N-alkynyl-2-(substituerede aryloxy)alkylthio-amidderivater som fungicider
ATE312827T1 (de)	2005-12-15	3-substituierte-4-pyrimidonderivate
NO20041235L (no)	2004-03-24	Kinolinderivater som neuropeptid Y antagonister
NO20050665L (no)	2005-04-18	Pyrrolidonderivater som MAOE inhibitoere
NO20030100L (no)	2003-01-09	Pleuromutilinderivater som har antibakteriell aktivitet
FI20020846A7 (fi)	2003-11-04	Sakset
NO20043794L (no)	2004-09-10	Benzensulfonamidderivater som antipsykotiske midler
DK1429607T3 (da)	2007-08-13	Delta-1-pyrroliner som pesticider
DE50213466D1 (de)	2009-05-28	Fungizide wirkstoffkombinationen
NO20034949L (no)	2003-11-06	Sulfonamider
NO20044092L (no)	2004-09-27	Oftalmisk sammensetning som innbefatter ascomycin
DK1556377T3 (da)	2006-10-23	Cyclopropylthienylcarboxamider som fungicider
NO20033234L (no)	2003-09-22	Karotenoider som antihypertensjonsmidler
FI20011300A0 (fi)	2001-06-19	Sprinkleri

Legal Events

Date	Code	Title	Description
2023-01-09	MK1K	Patent expired